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Quantifying the public’s view on social value judgments in 1 
vaccine decision-making: a discrete choice experiment 2 
Abstract 3 
Vaccination programs generate direct protection, herd protection and, occasionally, 4 
side effects, distributed over different age groups. This study elicits the general public’s 5 
view on how to balance these outcomes in funding decisions for vaccines. We 6 
performed an optimal design discrete choice experiment with partial profiles in a 7 
representative sample (N=1499) of the public in the United Kingdom in November 8 
2016. Using a panel mixed logit model, we quantified, for four different types of 9 
infectious disease, the importance of a person’s age during disease, how disease was 10 
prevented—via direct vaccine protection or herd protection—and whether the vaccine 11 
induced side effects. Our study shows clear patterns in how the public values 12 
vaccination programs. These diverge from the assumptions made in public health and 13 
cost-effectiveness models that inform decision-making. We found that side effects and 14 
infections in newborns and children were of primary importance to the perceived value 15 
of a vaccination program. Averting side effects was, in any age group, weighted three 16 
times as important as preventing an identical natural infection in a child whereas the 17 
latter was weighted six times as important as preventing the same infection in elderly 18 
aged 65-75 years. These findings were independent of the length or severity of the 19 
disease, and were robust across respondents’ backgrounds. We summarize these 20 
patterns in a set of preference weights that can be incorporated into future models. 21 
Although the normative significance of these weights remains a matter open for 22 
debate, our study can, hopefully, contribute to the evaluation of vaccination programs 23 
beyond cost-effectiveness.   24 
 25 
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1. Introduction 30 
Economic evaluation methods such as cost-effectiveness analysis (CEA) are common 31 
components in public funding decisions for vaccines (Drummond, Sculpher, Torrance, 32 
O'Brien, & Stoddard, 2005; Walker, Hutubessy, & Beutels, 2010). They feature in the 33 
standard evidence considered by e.g. the Advisory Committee on Immunization 34 
Practices in the US, the Joint Committee on Vaccination and Immunization in England, 35 
the World Health Organization and non-governmental organizations such as the Bill & 36 
Melinda Gates Foundation (Ricciardi et al., 2015). At the same time, it is widely 37 
acknowledged that these evaluation frameworks have important shortcomings and 38 
that they alone offer insufficient basis for making fair and efficient vaccine funding 39 
decisions (Cookson, Drummond, & Weatherly, 2009; Dukhanin et al., 2018). There is 40 
a growing literature about the limits of CEA in assessing the value of vaccination 41 
(Barnighausen, Bloom, Cafiero-Fonseca, & O'Brien, 2014; Bloom, 2011; Bloom, Fan, 42 
& Sevilla, 2018; Luyten & Beutels, 2016).  43 
One important criticism is that CEA is limited in how it values the consequences of 44 
vaccination. Summary outcome measures [such as e.g. infections prevented or 45 
Quality-Adjusted Life Years (QALYs) gained] neglect the particular social context in 46 
which these outcomes occur. Nonetheless, such contextual features are important 47 
aspects to consider when evaluating a vaccination strategy. Vaccination induces 48 
disease protection in those who become vaccinated, but it also creates herd protection 49 
(or indirect effects in third parties because of reduced pathogen transmission (Fine, 50 
Eames, & Heymann, 2011)) and, occasionally, adverse clinical side effects. There are 51 
qualitative differences between these direct, herd and side effects. Creating herd 52 
protection can be of particular ethical value (e.g. to protect vulnerable groups who 53 
otherwise cannot protect themselves) and there is a profound psychological impact of 54 
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vaccine-induced side effects. Moreover, the distribution of these three different effect 55 
types over different age groups is important. Side effects can be concentrated in one 56 
age group despite indirect protection from reduced transmission benefitting either the 57 
wider population, or in some cases a different age group entirely (Anderson & May, 58 
1991). Examples include protecting the elderly through childhood influenza 59 
vaccination or future generations through a polio eradication program. Such broader, 60 
distributive aspects of vaccination are important but they remain neglected in standard 61 
cost-effectiveness or public health impact models.  62 
Several notable examples illustrate that this broader social context of health outcomes 63 
needs to be considered in vaccine decision-making (Schwartz & Caplan, 2017). For 64 
instance, vaccines against rotavirus (Rotashield®) and pertussis (whole cell pertussis 65 
vaccine) were withdrawn from many countries because of a perceived risk of side 66 
effects, even though from a medical perspective the benefit from vaccination largely 67 
outweighed any potential risk (Blume & Zanders, 2006; Granstrom, 2011; Lynch et al., 68 
2006). Also, despite persuasive economic and public health benefits of childhood 69 
influenza vaccination, few countries have actually implemented such a preventive 70 
strategy, due in large part to concerns about the social acceptability and equity of 71 
targeting vaccination at children to protect the wider population (McGuire, Drummond, 72 
& Keeping, 2016). And, in many countries introduction of an effective varicella 73 
vaccination program has been delayed because of concerns about the possible 74 
‘exogenous boosting effect’ and its social repercussions, i.e. that reduced chickenpox 75 
transmission among children (due to varicella vaccination) might temporarily increase 76 
shingles incidence among older generations (Luyten, Ogunjimi, & Beutels, 2014).  77 
Misjudging ethical norms and social sensitivities in vaccination policy by over-relying 78 
on CEA can have important implications. It may affect the perceived equity of a 79 
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program, its support by the public and its long-term sustainability (Charo, 2007; 80 
Feudtner & Marcuse, 2001; Salmon et al., 2006; Yaqub, Castle-Clarke, Sevdalis, & 81 
Chataway, 2014) (Hornsey, Harris, & Fielding, 2018; Tomeny, Vargo, & El-Toukhy, 82 
2017). It can invoke public backlash to the vaccine, leading to reduced uptake, 83 
increased vaccine hesitancy and reduced overall effectiveness of the program (Bauch 84 
& Earn, 2004; Bhattacharyya, Bauch, & Breban, 2015; Ndeffo Mbah et al., 2012). 85 
Therefore, an empirical evidence-base is needed about the public’s view on the key 86 
value judgments that need to be made in vaccine funding decisions (Bombard, 87 
Abelson, Simeonov, & Gauvin, 2011; Field & Caplan, 2012; Luyten, Dorgali, Hens, & 88 
Beutels, 2013; Makarovs & Achterberg, 2017; Poland & Marcuse, 2011). Such 89 
evidence can complement formalized appraisals like CEA, stimulate deliberation and 90 
discussion on how to prioritize vaccines within a budget constraint and, moreover, it 91 
can be explored whether such evidence can become quantitatively integrated into 92 
formal decision frameworks in some sort of ‘extended’ or ‘weighted’ CEA (Cookson et 93 
al., 2009; Fleurbaey, Luchini, Muller, & Schokkaert, 2013).  94 
The objective of this study is to address this challenge by analyzing how the population 95 
in the United Kingdom prioritizes vaccination programs and to investigate whether its 96 
values diverge from the assumptions that are implicitly underlying CEA. We use a 97 
discrete choice experiment (DCE) among a representative sample of the population in 98 
the United Kingdom (UK) to investigate, for four different types of infectious diseases, 99 
the role played by different age groups in a program’s overall evaluation and the extent 100 
to which it matters whether these age groups are affected by either direct, herd or side 101 
effects. We summarize these findings into a set of social preference weights for health 102 
outcomes (e.g. QALYs) that could be incorporated into economic evaluation or public 103 
health impact models.  104 
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 105 
2. Methods  106 
DCEs are a widely used survey method to quantify individuals’ preferences (Louviere, 107 
Hensher, & Swait, 2000; Ryan, Gerard, & M, 2008) (for a general review of 108 
applications, see (de Bekker-Grob, Ryan, & Gerard, 2012)). Participants are presented 109 
with a series of choices, usually between two goods described by the same attributes 110 
but differing in their attribute levels. By observing respondents’ preferred choices, 111 
researchers can infer how the value of the competing options is determined by the 112 
attributes of the product. In our case, we observe how people prioritize between 113 
vaccination programs based on the number of direct, herd and side effects generated 114 
by the program, and their distribution over different age groups. This allows us to 115 
estimate a utility function that describes how the public values vaccination programs, 116 
taking into account the different types of vaccine effect and their distribution. 117 
 118 
2.1 Choice context 119 
For all of their choices, respondents were randomly assigned one of four disease 120 
scenarios (see Appendix A). [insert link to appendix] These were introduced before 121 
the start of the DCE. After five choice sets this disease was presented again to the 122 
respondent as a reminder. The four disease profiles were described as (1) severe—123 
lasting nine days, (2) mild—lasting nine days, (3) severe—lasting 160 days, and (4) 124 
mild—lasting 160 days. Influenza and pertussis were used as proxies for an acute 125 
severe and a longer lasting milder disease, respectively (van Hoek et al., 2014; van 126 
Hoek, Underwood, Jit, Miller, & Edmunds, 2011). To avoid participants’ preconceived 127 
ideas, the diseases were unnamed and only described to participants by means of 128 
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severity using the generic descriptors of the dimensions of a standard instrument to 129 
measure health-related quality of life, the EuroQoL EQ-5D-3L, based on average 130 
reported values for both influenza and pertussis (van Hoek et al., 2014; van Hoek et 131 
al., 2011). To exclude considerations about age differences in remaining life 132 
expectancy, we explicitly told the participants that the diseases were not fatal.  133 
Before every choice set we told respondents the following: “the government has to 134 
choose between two vaccination programs that will each be used in 100 000 people. 135 
Considering your conviction about vaccination policy, which program do you think the 136 
government should choose? Both options are equally costly, and identical in every 137 
way except for the following 5 differences.”  138 
 139 
2.2 Attributes and levels of vaccination programs 140 
To develop the final attributes and levels of the vaccine programs included in the DCE, 141 
we followed a three stage iterative process. We performed a literature search of other 142 
vaccine-related DCEs to assess the choice context and which attributes were typically 143 
considered. These attributes were disease incidence, case fatality risk, economic 144 
impact, duration of illness and duration of vaccine protection, severity of illness and 145 
severity of side effects, and various personal characteristics including age, gender and 146 
willingness/ability to get vaccinated. (de Bekker-Grob et al., 2010; Hofman et al., 2014; 147 
Lambooij et al., 2015; Sadique, Devlin, Edmunds, & Parkin, 2013; Veldwijk, Lambooij, 148 
Bruijning-Verhagen, Smit, & de Wit, 2014) From this list, we took the attributes that 149 
were, in combination with the four disease profiles, best suited to answer our research 150 
question. We presented several attribute combinations to a convenience sample of lay 151 
persons, colleagues and collaborators at the market research company in a pilot 152 
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questionnaire, which we revised in response to received comments. We re-iterated 153 
this process until we found the right form for the DCE from which, with a relatively 154 
simple set of in total five core attributes (Table 1), we could robustly calculate 155 
preference weights.  156 
The first two attributes described the age group targeted for vaccination and 157 
magnitude of the direct effects among those vaccinated. The third attribute described 158 
the number of side effects occurring among those vaccinated. The side effects of 159 
vaccination were presented in the DCE as identical to an episode of the disease that 160 
the vaccine usually prevents, in order to enable a direct comparison between the three 161 
effect types. Not doing so would have meant using a second health profile within one 162 
choice option (one for the disease and one for the side effects) and this would also 163 
have made the experiment substantially more difficult for the participants. The fourth 164 
and fifth attribute described the magnitude of the herd effects and the age group that 165 
received them. We decided to focus only on the morbidity aspects of illness because 166 
including mortality would require additional attributes for infected people in order to 167 
account for their differing life expectancy.  168 
For direct and herd protection we used 1000, 3000 or 5000 disease episodes 169 
prevented per 100,000 people vaccinated (an attack rate of 1-5% for a vaccine with a 170 
100% efficacy), and for side effects 100, 300 or 500 disease episodes per 100,000 171 
people vaccinated (an attack rate of 0.1-0.5%). For direct protection and side effects, 172 
we considered the following three age groups: children aged between 3 months and 173 
3 years of age, adults aged between 30 and 50 years, and elderly aged between 65 174 
and 75 years. The age groups for herd protection represented groups that, in the case 175 
of the first two, are often difficult to vaccinate for immunological reasons: young 176 
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children under 3 months, elderly above 80 years and unvaccinated adults between 30 177 
and 50 years.  178 
 179 
(insert Table 1) 180 
 181 
We depicted both the age group and quantity of cases avoided or caused by 182 
vaccination using simple graphics (Ancker, Senathirajah, Kukafka, & Starren, 2006) 183 
(Figure 1). To explicitly investigate the assumption whether individuals ultimately look 184 
at the total impact of the program and to reduce the chance that respondents would 185 
adhere to a simple counting heuristic without reflection, we presented the net number 186 
of disease cases averted for each strategy separately (the sum of direct and herd 187 
effects minus side effects).  188 
 189 
(insert Figure 1) 190 
 191 
2.3 Experimental design of the choice sets 192 
The design of a DCE refers to the number and composition of choice sets presented 193 
to each participant (Reed Johnson et al., 2013). A set of 45 choice sets was selected 194 
out of the 58,806 possible choice sets (see Appendix B for more info on the selection 195 
process [insert link to appendix]) and distributed over three survey versions, so to limit 196 
the number of choice sets to be completed per respondent to 15. Therefore, each of 197 
the four disease profiles was represented in three different surveys (see Figure 2).  198 
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 199 
(Insert Figure 2) 200 
 201 
The choice alternatives (i.e. profiles) themselves were ‘partial profiles’ (Kessels, 202 
Jones, & Goos, 2015). We varied and highlighted the levels of two to four of the five 203 
attributes in the choice sets and kept the remaining attribute(s) constant so that 204 
respondents did not have to simultaneously trade-off all five dimensions per choice 205 
(see Appendix B [insert link to appendix]). Limiting the cognitive burden for 206 
respondents in a DCE increases the validity and reliability of their answers (Dellaert, 207 
Donkers, & van Soest, 2012). The design we generated was ‘D-optimal’ in a Bayesian 208 
framework fitting with a multinomial logit (MNL) model for the attributes’ main effects 209 
and six interactions between the two age attributes (direct and herd effects) and the 210 
three magnitude attributes we deemed to be important a priori. We chose a Bayesian 211 
framework to integrate prior information on the respondents’ likely preferences 212 
(Kessels, Jones, Goos, & Vandebroek, 2011) (see Appendix C [insert link to 213 
appendix]). The Bayesian D-optimal design then results in the smallest possible 214 
standard errors for the utility estimates at the given sample size.   215 
 216 
2.4 Sample  217 
After the design, we tested our survey among a pilot sample of the online panel (N=69) 218 
to confirm that respondents could fully understand and complete the survey. Based on 219 
the feedback from this pilot sample we judged that the experiment was understandable 220 
and that no further changes were needed.  221 
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From a consumer panel of 1 million UK members, 9613 random panelists were 222 
approached to participate in “a scientific study on resource allocation in healthcare”. 223 
Of these people, 4144 (43%) responded to the invitation. We recruited 1950 of them 224 
to fulfill predetermined quotas to provide a representative sample of the UK population 225 
in terms of gender, socio-economic strata (indicated by the occupation of the head of 226 
the household), age groups (20-29, 30-39, 40-49, 50-59, 60+ years), and urban vs. 227 
rural background.  228 
The DCE was conducted in November 2016. An email containing a link to the survey 229 
website was sent to participants and by clicking on the link respondents consented to 230 
participate, although they were free to stop or close the survey at any point. All 231 
respondents received a nominal incentive for study completion (£0.50 per 12-minute 232 
questionnaire). Before completing the DCE, respondents were asked to administer a 233 
survey tool to measure vaccine hesitancy (Larson et al., 2015), and were asked social-234 
demographic questions and whether they have or had children. After the DCE, we 235 
asked about their experience with severe diseases, their interpretation of the validity 236 
of the answers they provided and the overall difficulty of the DCE survey. 237 
We obtained informed consent from all respondents and ethical approval of the study 238 
from the Ethics Committee of the London School of Hygiene & Tropical Medicine (Ref 239 
10335). We conducted the research in accordance with the Code of Conduct of the 240 
Market Research Society, which ensured that information is collected for research 241 
purposes only, is kept confidential, and respondent anonymity is guaranteed.  242 
 243 
2.5 Data analysis 244 
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To quantify the weight of the five attributes and their levels in the utility attributed to a 245 
vaccination strategy, a panel mixed logit model (fitted by the Hierarchical Bayes 246 
method (Train, 2009)) was used (see Table 3). The model involved seven main 247 
effects: four related to the two three-level categorical attributes describing the utility 248 
impact of a change in the targeted age group in direct and herd effects, and three 249 
related to the continuous attributes describing the impact of a change in the absolute 250 
number of disease cases via direct effects, side effects and herd effects. Besides 251 
these seven main effects the model also includes attribute interaction effects, 252 
indicating the additional change in utility because of a particular combination of 253 
attribute levels. We computed the overall significance of the attributes using likelihood 254 
ratio (LR) tests and measured the relative importance of the attributes by the logworth 255 
statistic (i.e. –log10 (p-value of the LR-test)). The coefficients of the logit model were 256 
obtained by estimating the a priori model, i.e. the model with the utility function that 257 
seemed most appropriate when planning the DCE, and subsequently dropping the 258 
non-significant model terms until we obtained a final model in which all effects had 259 
significant explanatory value at the 5% level. Models were fitted using the JMP 13 Pro 260 
Choice platform (based on 10,000 iterations, with the last 5000 used for estimation) 261 
assuming normally distributed parameters with no correlation between the attributes. 262 
Combining the main and interaction effects, this model allows calculating the additional 263 
utility of a vaccination program generated per additional health effect, i.e. per type of 264 
effect per age group (see the nine variations in Table 3). The 95% confidence intervals 265 
for the equity weights were estimated using the Delta method (Bliemer & Rose, 2013).  266 
 267 
We investigated heterogeneity in respondents’ preferences in two ways. First, by 268 
exploring the influence of the observed respondent characteristics on the average 269 
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preferences and, second, by studying the unobserved preference heterogeneity by 270 
means of a hierarchical cluster analysis on the subject-specific estimates resulting 271 
from the Hierarchical Bayes approach. We favoured this two-stage modelling method 272 
as it performs equally well as one-stage modelling methods such as latent class 273 
modelling (Crabbe, Jones, & Vandebroek, 2013; Kessels, Jones, & Goos) while 274 
enabling us to parsimoniously derive the preference weights and their 95% confidence 275 
intervals.     276 
 277 
3. Results 278 
 279 
3.1 Response 280 
A total of 1546 respondents out of 1950 (79%) who were sent the questionnaire 281 
completed it, of which 47 (3%) indicated that the questions were too difficult or their 282 
answers invalid, leaving 1499 questionnaires for analysis. Our final sample was 283 
sufficiently representative of the UK population in terms of gender, family size, socio-284 
economic status and education level (Table 2).  285 
 286 
(insert Table 2) 287 
 288 
3.2 Main effects and calculated weights 289 
Across all questionnaires, respondents made a total of 22,485 choices between 290 
vaccination programs. There was no significant effect observed of which of the three 291 
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survey versions a participant received. Respondents did not systematically choose the 292 
program with the highest overall public health impact, i.e. the total of all prevented 293 
cases including direct, herd and side effects. In fact, only 99 respondents (6.6%) 294 
consistently opted for the most effective program in all of their choice sets. However, 295 
about half the respondents (738/1499) chose the most effective alternative in at least 296 
70% of their choices, indicating that the total effect on the disease burden is important, 297 
but not the only factor in prioritizing vaccination programs.  298 
Table 3 presents an overview of the incremental utility of the main effects and 299 
interactions. The vaccination program that was least preferred (i.e. yielding minimum 300 
utility) was one that targeted the elderly (65-75y), generated the lowest number of 301 
prevented cases, the highest number of side effects, and the lowest number of cases 302 
prevented via herd protection in unvaccinated adults. The most preferred program (i.e. 303 
yielding maximum utility) was one that targeted children, generated the highest 304 
number of prevented cases, the lowest number of side effects, and the highest number 305 
of cases prevented via herd protection in newborns.  306 
 307 
(insert Table 3) 308 
 309 
Using the same logit model, we then calculated preference weights for each effect 310 
type per age group. These weights act as a multiplicative factor to transform identical 311 
clinical symptoms into health effects with equal value in the public’s view. We 312 
compared the additional utility of a vaccination program that is generated through 313 
preventing one specific disease case relative to the utility gained through directly 314 
preventing a single disease case via vaccinating a child (Figure 3). These preference 315 
14 
 
weights reveal important patterns. First, preventing side effects of vaccination was 316 
highly preferable to preventing natural infections, even though the symptoms were 317 
equal in length and severity. The mean weight for side effects across all ages was -318 
2.93, meaning that avoiding one vaccine-induced infection was weighted equally to 319 
avoiding around three natural infections among children. This finding was consistent 320 
whether side effects occurred in children (-2.95 (95% CI: -3.21; -2.69)), adults (-3.16 321 
(95% CI: -3.51; -2.81)) or the elderly (-2.68 (95% CI: -2.98; -2.37)). Second, 322 
respondents preferred vaccination programs that prevented disease among newborns 323 
and children compared with those for adults and the elderly, even though the 324 
prevented disease burden was similar. One episode prevented in a newborn via herd 325 
protection was considered about twice as valuable as directly protecting an adult via 326 
vaccination. Third, the extent to which respondents preferred protecting adults and the 327 
elderly depends on the type of benefit conferred by the program. Direct effects were 328 
the preferred mode of protection for adults whereas herd effects were preferred for the 329 
elderly. Reducing disease burden by directly vaccinating adults (aged 30-50 years) 330 
was weighted equally to reducing disease burden in the elderly (aged 80+ years) via 331 
herd effects [0.75 (0.64; 0.85) compared to 0.67 (0.58; 0.76), respectively]. In contrast, 332 
reducing disease burden in adults (aged 30-50 years) by herd effects counted equally 333 
to reducing disease burden in elderly (aged 65-75 years) directly via vaccination (0.12 334 
(0.03; 0.20) compared to 0.16 (0.06; 0.25), respectively).  335 
 336 
(insert Figure 3) 337 
 338 
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From these results, we also calculated the number of infections needed to avert in 339 
order to obtain equal utility as that from protecting 100 children directly via vaccination 340 
(Table 4). Avoiding 100 infections in children via vaccination was considered 341 
equivalent to protecting 632 elderly (65-75 years) or 134 adults. In turn, these 342 
outcomes were equivalent to protecting 71 newborns, 865 adults or 150 elderly (>80y) 343 
via herd protection. Similarly, a vaccination strategy reduces its utility by causing side 344 
effects. Avoiding 34 side effects in children generates the same utility as preventing 345 
100 natural infections among the same age group.  346 
 347 
(insert Table 4) 348 
 349 
Figure 4 illustrates the significant interaction in our model between the age of the 350 
vaccinated group and the age of the herd protection recipients (see Table 3). This 351 
interaction must be understood as the additional utility that is given to (or taken away 352 
from) a vaccination program depending on the particular combination of age groups 353 
that are involved, regardless of the magnitude of direct, herd or side effects that are 354 
being generated. It presents the attractiveness of particular intergenerational 355 
vaccination strategies. Whereas a CEA perspective would consider all possible age 356 
combinations equally attractive (as long as they lead to the same number of infections 357 
prevented), our sample had clear intergenerational preferences over vaccination 358 
strategies. Any age group was deemed acceptable to vaccinate when there were herd 359 
protection benefits for newborns. To generate herd protection for adults, children were 360 
the most attractive age group. To generate it to protect the elderly >80, adults were 361 
deemed most appropriate. The least attractive intergenerational combination was 362 
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vaccinating elderly 65-75 years while generating herd protection in adults 30-50 years. 363 
The most attractive age combination was vaccinating children while generating herd 364 
protection in newborns.  365 
 366 
(insert Figure 4) 367 
 368 
3.3 Preferences across disease types and respondents 369 
As shown in Appendix D ([insert link to appendix], our results remained robust 370 
across all four different disease types: the equity weights were statistically equivalent, 371 
regardless of whether the condition was mild vs. severe or acute vs. chronic (indicated 372 
by a non-significant interaction effect in our model between the attributes and the 373 
disease type). Also, the appendix [insert link to appendix] illustrates that our findings 374 
also remained robust across most respondent characteristics: gender, age, 375 
occupation, level of education, urban-rural, socio-economic background, experience 376 
with severe illness or parental status. Although individuals with a low degree of vaccine 377 
hesitancy (indicated by high values on the ‘vaccine hesitancy scale’ (VHS) (Larson et 378 
al., 2015)) attributed less importance to side effects (p<0.0001), this effect was 379 
relatively small (a 10 unit increase in the VHS score (on a scale from 10 to 50) led to 380 
a 10% decrease in absolute magnitude of the utility for side effects (~0.03)).  381 
The hierarchical cluster analysis of the individual preferences (see methods) revealed 382 
two distinct groups of respondents: one group (N=564, Cluster 1) who attached almost 383 
no importance to the number of side effects (with a mean weight of -0.91 for side 384 
effects) and a larger group (N=935, Cluster 2) who valued this attribute fairly highly 385 
(with a mean weight of -4.40) (Table 3). This clustering explains the relatively high 386 
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variation across respondents for the weight estimate for side effects (the standard 387 
deviation to mean absolute value ratio of 0.043 for side effects is almost twice the ratio 388 
for direct and herd effects). We used a logistic regression to determine predictors of 389 
cluster membership. Cluster 1, who attached almost no importance to the number of 390 
side effects, was characterized by high values on the VHS, indicating little hesitancy 391 
(p<0.0001). On the other hand, cluster 2, who valued side effects more highly, was 392 
characterized by higher degrees of hesitancy on the VHS. However, the predictive 393 
power of this association for membership of the group was small (McFadden’s pseudo 394 
R2=0.6%), implying that there is much unexplained heterogeneity in the importance 395 
placed on side effects. 396 
 397 
  398 
18 
 
4. Discussion 399 
In this study, we used a discrete choice experiment to analyse and quantify how the 400 
public values the outcomes of vaccination programs. We observed several general 401 
preference patterns, which were robust across different lengths and severities of 402 
disease and respondent characteristics (socio-economic background, age, education 403 
and parenthood). We observed that most respondents did not make choices purely 404 
based on how to minimize the number of infections. In particular, individuals, on 405 
average, weighted one averted instance of a side effect equal to about three similarly 406 
severe natural infections in children and weighted one averted health outcome in 407 
children up to six times more than preventing similarly severe health outcomes in the 408 
elderly. Interestingly, our study has disentangled this latter phenomenon from the type 409 
of effect as we observed a different weight given to protecting older people depending 410 
on whether the benefits were directly vs. indirectly received. Our results support a duty 411 
of care principle to provide herd protection for the elderly and an aversion to protecting 412 
adults who are better able to protect themselves. The weight given to side effects when 413 
evaluating a vaccination program was divisive, splitting our sample into two clusters.  414 
Our study, as far as we are aware, is the first of its kind to quantify the important social 415 
value judgements that need to be made in vaccine funding decisions. Although this 416 
limits comparability, our findings are in line with what can be learned from other study 417 
domains. The finding that individuals weighted one averted instance of a side effect 418 
equal to about three similarly severe natural infections in children can be explained 419 
with general theory on decision-making. For instance, well-documented psychological 420 
phenomena such as ‘loss aversion’ (Kahneman & Tversky, 1979) (overvaluing risks 421 
and losses over opportunities and gains), the ‘act-omission bias’ (Spranca, Minsk, & 422 
Baron, 1991) [judging the effects of an act (becoming vaccinated) differently from 423 
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identical effects resulting from an omission (becoming infected)], or ‘hyperbolic 424 
discounting’ (Frederick, Loewenstein, & O'Donoghue, 2002) [overvaluing the present 425 
(in which side effects occur) over the future (in which disease prevention will occur)] 426 
suggest that people put an extraordinary weight on side effects when evaluating a 427 
vaccination strategy. Moreover, also empirical studies that have investigated people’s 428 
(stated) choices about whether or not they would personally become vaccinated with 429 
a particular vaccine (e.g. (Sadique et al., 2013; Seanehia et al., 2017)) generated 430 
findings that highlight the extraordinary weight of side effects. The preference given to 431 
health benefits in younger people (newborns and children), up to six-fold, is also in line 432 
with related studies on ‘ageism’ in other contexts of healthcare priority-setting 433 
(reviewed in (Gu, Lancsar, Ghijben, Butler, & Donaldson, 2015) and discussed 434 
elsewhere, e.g. (Bognar, 2015; Tsuchiya, 2000)).  435 
It is important to study which aspects of health policy choices matter most to the public. 436 
This is especially true in vaccination where public trust, goodwill and participation are 437 
sensitive and key to success (Cooper, Larson, & Katz, 2008). There is a growing 438 
concern that public and political trust in scientific evidence is eroding, particularly in 439 
the context of vaccination (Karafillakis et al., 2016; Larson, Cooper, Eskola, Katz, & 440 
Ratzan, 2011; Leask, Willaby, & Kaufman, 2014). By being aware of the sensitivities 441 
around vaccination, decision makers can understand and address some of the root 442 
causes of vaccine hesitancy, adapt to concerns of the population and improve 443 
responses in communication strategies.(Diekema & American Academy of Pediatrics 444 
Committee on, 2005) Our findings provide empirical evidence on how to set vaccine 445 
priorities in line with public preferences. There is an important debate over the extent 446 
to which the public’s opinion should drive resource allocation in healthcare (see e.g. 447 
(Hausman, 2004, 2015)). But, many believe that the values of the public, who pays for 448 
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healthcare, should at least somehow be acknowledged in the decision-making 449 
process. In the context of vaccination, where public support and participation is key to 450 
success, this concern becomes particularly crucial. Therefore, our results can be 451 
useful additions to vaccine appraisals. They can provide guidance in specific 452 
epidemiological cases where CEA does not provide the answers needed. For 453 
instance, our results would suggest that, despite their attractiveness in terms of cost-454 
effectiveness, the public may not support a childhood influenza vaccination program 455 
that mainly benefits adults or elderly (Baguelin et al., 2013), because preventing side 456 
effects in vaccinated children is preferred over preventing disease burden among 457 
adults and elderly. Furthermore, our study suggests that a childhood varicella-zoster 458 
vaccination program, in the case that it protects children against varicella disease at 459 
the expense of increased zoster in the elderly (the ‘exogenous boosting hypothesis’), 460 
might be justifiable. In contrast, previous analyses where QALY losses for children are 461 
weighted equally to those for the elderly find that the increased burden in the elderly 462 
offsets the QALY gains in children and determine the program not cost-effective 463 
(Brisson, Edmunds, & Gay, 2003; Luyten et al., 2014).  464 
Our results can also be directly incorporated into economic evaluations as sensitivity 465 
analyses to better align the underlying assumptions of CEA with the values of the 466 
population. Our estimated preference weights can be used in decision-analytic models 467 
as a parameter to weight QALYs or infections according to their ‘social value’. This 468 
would re-adjust the (equal) weight that QALYs receive in CEA according to how 469 
important people think that the age of the QALY-recipient is and whether the benefit 470 
was generated through direct protection, herd immunity or (avoiding) side effects. 471 
There is an increased interest in such ‘extended’, ‘distributive’ or ‘equity-weighted’ 472 
economic evaluation (see e.g. (Asaria, Griffin, & Cookson, 2016; Bleichrodt, 1997; 473 
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Cookson et al., 2009; Dolan, 1998; Fleurbaey et al., 2013; Nord, Pinto, Richardson, 474 
Menzel, & Ubel, 1999; Round & Paulden, 2017; Samson et al., 2017)), but, to our 475 
knowledge, such studies do not exist for the evaluation of vaccines. Our estimates are 476 
developed particularly for this context, and provide an opportunity to do so.  477 
There are several limitations. We did not include any mortality effects, nor did we 478 
include a difference in severity between the three vaccine effects, even though this 479 
would be more realistic (as side effects of vaccines are usually milder than the disease 480 
being prevented). We chose not to include these aspects because we wanted to avoid 481 
increasing the complexity of the survey and reducing the validity of the respondents’ 482 
answers by adding a second disease profile. Also, keeping the disease outcome 483 
constant over age groups and effects enabled trade-offs that were wholly reflective of 484 
the preference between age groups and effects instead of also reflecting additional 485 
considerations about disease severity. We also chose to present the number of side 486 
effects rather than its complement the number of vaccinated people without side 487 
effects. This framing may have played a role in the observed weight for side effects. 488 
The alternative framing would probably have drawn less attention to side effects and 489 
might have generated smaller weights. We however wanted people to make explicit 490 
trade-offs between side effects with protective benefits and chose for the more direct 491 
framing. Using the alternative is a suggestion for further research.  Also, we used 492 
generic disease profiles based on a description in EQ-5D terms to minimize 493 
respondents making personal associations to the disease and vaccine when we would 494 
have named the diseases (e.g. ‘flu’ or ‘whooping cough’), but this may also have 495 
increased the level of abstraction and reduced the level of personal involvement. A 496 
suggestion for further research is to repeat our study with named diseases and to test 497 
whether our finding that the disease profile did not matter to people’s preferences is 498 
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confirmed. Another limitation is that, while our sample was broadly representative of 499 
the UK population, it was recruited from an online panel where membership may be 500 
associated with unobserved characteristics (e.g. interest in technology).  501 
In conclusion, our study demonstrates clear and robust preference patterns in how 502 
people value the impact of vaccination programs. A large majority of respondents had 503 
a strong preference to minimize side effects and to prevent disease among newborns 504 
and children. Our observations provide quantitative evidence about public preferences 505 
around important and sensitive but neglected trade-offs in vaccine policy decision-506 
making, and can hopefully inspire further research and discussion.   507 
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Table 1. Attributes and levels used in the DCE 698 
Attribute Level 
Age of vaccinated group (N=100 000) Children (3 months -  3 years) 
Adults (30-50 years) 
Elderly (65-75 years) 
Disease episodes prevented in 
vaccinated group  
1000 cases 
3000 cases 
5000 cases 
Number of vaccine-induced side-effects 100 cases 
300 cases 
500 cases 
Disease episodes prevented via herd 
protection 
1000 cases 
3000 cases 
5000 cases 
Age of people receiving herd protection Newborns (<3 months) 
Adults (30-50 years) 
Elderly (>80 years) 
 699 
  700 
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 701 
Table 2: Respondent characteristics. 702 
 Sample UK population* 
Total recruited 1546   
Excluded for analysis 47  
Included in the analysis 1499 (100%)  
Gender   
Male 703 (47%) 49% 
Female 796 (53%) 51% 
Age (years)   
20-29 296 (20%) 13% 
30-39 285 (19%) 13% 
40-49 288 (19%) 14% 
50-59 308 (21%) 13% 
60 and over 322 (21%) 23% 
Living in a city with more than 10,000 
inhabitants  
1011 (67%) 83% 
Social grades based on the profession of the 
highest paid household member  
  
A (upper middle class) 85 (6%) 4% 
B (middle class) 297 (20%) 23% 
C1 (lower middle class) 385 (26%) 27% 
C2 (skilled working class) 330 (22%) 21% 
29 
 
 703 
*UK population data 2016: Office for National Statistics https://www.gov.uk/government/publications  704 
**Percentage of UK families living with dependent children (<18 years old) 705 
 706 
D (working class) 72 (5%) 16% 
E  (non-working) 330 (22%) 9% 
Education level   
No qualifications 48 (3%) 15% 
Secondary education  322 (21%) 14.2% 
Post-secondary education 288 (19%) 14.5% 
Vocational qualification 254 (17%) 20.3% 
Undergraduate degree, Post-graduate 
degree & Doctorate  
427 (39%) 30% 
Not sure 2 (0.1%) / 
Having children   
No children 585 (39%) 42% 
Children aged 0-4 years 168 (11%) 42%** 
Children aged 5-20 years 358 (24%) / 
Children aged over 20 years 388 (26%) 15% 
Exposure to poor health    
Participant affected by poor health 407 (27%)  
Close friends or family of the participant 
affected by poor health 
470 (31%)  
Neither participant nor close friends nor 
family affected by poor health 
622 (41%)  
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 712 
 713 
 714 
 715 
 716 
 717 
 718 
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 720 
Table 3. Attributes that affected respondent choices, based on panel mixed logit model estimates (means and standard 721 
deviations) with p-values from likelihood ratio (LR) tests for significant attribute effects.  722 
Model term Posterior mean Posterior std dev Subject std dev P-value 
Cases prevented in unvaccinated by herd effects  
(per 1000 cases) 0.715 0.018 0.101 <0.0001 
Cases prevented in vaccinated by direct effects (per 1000 
cases) 0.619 0.018 0.100 <0.0001 
Cases of side effects in vaccinated (per 100 cases) -0.285 0.012 0.110 <0.0001 
Age of unvaccinated  
 
 
[Newborns <3m] 0.614 0.048 0.090 <0.0001 
[Adults 30-50y] -0.597 0.043 0.105   
[Elderly >80y] -0.017  NA  NA   
Age of unvaccinated*Cases 
prevented in vaccinated by 
direct effects 
[Newborns <3m] -0.043 0.009 0.054 <0.0001 
[Adults 30-50y] 0.071 0.009 0.041   
[Elderly >80y] -0.028  NA  NA   
Age of vaccinated  
 
[Children 3m-3y] 0.305 0.040 0.063 <0.0001 
[Adults 30-50y] 0.142 0.048 0.062   
32 
 
 [Elderly 65-75y] -0.446  NA  NA   
Age of unvaccinated*Age of 
vaccinated  
 
 
 
 
 
 
 
[Newborns <3m]* [Children 3m-
3y] -0.131 0.036 0.053 <0.0001 
[Newborns <3m]* [Adults 30-
50y] -0.210 0.041 0.065   
[Newborns <3m]* [Elderly 65-
75y ] 0.341  NA  NA   
[Adults 30-50y]* [Children 3m-
3y] 0.250 0.052 0.044   
[Adults 30-50y]* [Adults 30-50y] -0.079 0.049 0.045   
[Adults 30-50y]* [Elderly 65-
75y] -0.171  NA  NA   
[Elderly >80y]* [Children 3m-3y] -0.119  NA  NA   
[Elderly >80y]* [Adults 30-50y] 0.289  NA  NA   
[Elderly >80y]* [Elderly 65-75y] -0.170  NA  NA   
Age of vaccinated*Cases of 
side effects in vaccinated 
[Children 3m-3y] -0.032 0.008 0.040 <0.0001 
[Adults 30-50y] -0.037 0.009 0.044   
[Elderly 65-75y] 0.069  NA  NA   
[Newborns <3m] 0.052 0.009 0.048 <0.0001 
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Note: Mean estimates corresponding to the last level of an attribute, either as a main effect or involved in an interaction, are italicized and calculated as minus 723 
the sum of the estimates for the other levels of that attribute; NA means ‘not assigned’. 724 
Age of unvaccinated*Cases 
prevented in unvaccinated by 
herd effects 
[Adults 30-50y] -0.005 0.008 0.043   
[Elderly >80y] -0.047  NA  NA   
Age of vaccinated*Cases 
prevented in vaccinated by 
direct effects 
[Children 3m-3y] 0.051 0.010 0.044 <0.0001 
[Adults 30-50y] -0.032 0.009 0.037   
[Elderly 65-75y] -0.019  NA  NA   
34 
 
Table 4. Number of infections to prevent to gain equal utility, with 95% 725 
confidence intervals.  726 
Age group of 
vaccine effect 
Direct effects Herd effects Side effects 
Newborns  
(<3 months) 
NA 71  
[66; 76] 
NA 
Children  
(3 months – 3 years) 
100  
[index] 
NA -34  
[-37; -31] 
   Cluster 1: -221 [-340; -102]  
   Cluster 2: -21 [-23; -20] 
Adults 
(30–50 years) 
134  
[115; 153] 
865  
[242; 1487] 
-32 
 [-35; -28] 
   Cluster 1: -72 [-93; -51] 
   Cluster 2: -23 [-25; -20] 
Elderly 
(65–75 years) 
632  
[255; 1010] 
NA -37  
[-42; -33] 
   Cluster 1: -113 [-163; -64] 
   Cluster 2: -25 [-27; -22]  
Elderly  
(>80 years) 
NA 150  
[130; 169] 
NA 
Note: Cluster 1 and 2 have 564 and 935 respondents, respectively; NA refers to combinations of 727 
attribute levels not included in the choice profiles. 728 
  729 
35 
 
Figure 1. Example of a choice set. 730 
 731 
Figure 2. Schematic representation of the different arms of the questionnaire. 732 
For each disease stratum, there was also an equal sampling over the socio-733 
economic groups (25% A+B; 25% C1; 25% C2; 25% E+D). 734 
 735 
Figure 3. Utility weights representing public preferences for identical health 736 
outcomes with different attributes, with 95% confidence intervals. 737 
 738 
Figure 4. Intergenerational preferences: interaction effects between the age 739 
group vaccinated and the age group receiving herd protection effects. 740 
Marginal utility values consist of main effects of the attributes involved and 741 
their interaction effect.  742 
 743 
 744 
